國立虎尾科技大學 |

Managing Metastatic Prostate Cancer In Your Urological Oncology Practice

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Managing Metastatic Prostate Cancer In Your Urological Oncology Practice/ edited by K.C Balaji.
other author:	Balaji, K.C.
Description:	XIII, 280 p.online resource. :
Contained By:	Springer Nature eBook
Subject:	Urology. -
Online resource:	https://doi.org/10.1007/978-3-319-31341-2
ISBN:	9783319313412

Managing Metastatic Prostate Cancer In Your Urological Oncology Practice
Managing Metastatic Prostate Cancer In Your Urological Oncology Practice[electronic resource] /edited by K.C Balaji. - 1st ed. 2016. - XIII, 280 p.online resource.

Introduction -- Pathophysiology of Castration-Resistant Prostate Cancer -- Androgen Receptor Signaling in Castration Resistant Prostate Cancer -- Non-Androgen Signaling Pathways in Castration-Resistant Prostate Cancer -- Predictive Models in Castration Resistant Prostate Cancer -- Docetaxel in Advanced and Castration Resistant Prostate Cancer -- Combination Treatment Strategies with Docetaxel in Patients with Metastatic Prostate -- Cancer Vaccines in Castration Resistant Prostate Cancer – An evolution in design -- Abiraterone for the treatment of mCRPC -- Enzalutamide in Metastatic Castration Resistant Prostate Cancer -- Radium-223 in Metastatic Castrate Resistant Prostate Cancer -- Cabazitaxel for the Treatment of Prostate Cancer -- Sequencing Therapies in Metastatic Castration Resistant Prostate Cancer -- Bone Preservation Strategies for Men on Androgen Deprivation Therapy -- Novel Therapies in Castration-Resistant Prostate Cancer.

This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information.

ISBN: 9783319313412

Standard No.: 10.1007/978-3-319-31341-2doiSubjects--Topical Terms:

645258
Urology.

LC Class. No.: RC870-923.2

Dewey Class. No.: 616.6

Managing Metastatic Prostate Cancer In Your Urological Oncology Practice
LDR:03198nam a22004095i 4500 001 980194
003 DE-He213
005 20200630173127.0
007 cr nn 008mamaa
008 201211s2016 gw | s |||| 0|eng d
020 $a 9783319313412 $9 978-3-319-31341-2
024 7 $a 10.1007/978-3-319-31341-2 $2 doi
035 $a 978-3-319-31341-2
050 4 $a RC870-923.2
050 4 $a RC875-899.5
072 7 $a MJS $2 bicssc
072 7 $a MED088000 $2 bisacsh
072 7 $a MJS $2 thema
082 0 4 $a 616.6 $2 23
245 1 0 $a Managing Metastatic Prostate Cancer In Your Urological Oncology Practice $h [electronic resource] / $c edited by K.C Balaji.
250 $a 1st ed. 2016.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a XIII, 280 p. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Introduction -- Pathophysiology of Castration-Resistant Prostate Cancer -- Androgen Receptor Signaling in Castration Resistant Prostate Cancer -- Non-Androgen Signaling Pathways in Castration-Resistant Prostate Cancer -- Predictive Models in Castration Resistant Prostate Cancer -- Docetaxel in Advanced and Castration Resistant Prostate Cancer -- Combination Treatment Strategies with Docetaxel in Patients with Metastatic Prostate -- Cancer Vaccines in Castration Resistant Prostate Cancer – An evolution in design -- Abiraterone for the treatment of mCRPC -- Enzalutamide in Metastatic Castration Resistant Prostate Cancer -- Radium-223 in Metastatic Castrate Resistant Prostate Cancer -- Cabazitaxel for the Treatment of Prostate Cancer -- Sequencing Therapies in Metastatic Castration Resistant Prostate Cancer -- Bone Preservation Strategies for Men on Androgen Deprivation Therapy -- Novel Therapies in Castration-Resistant Prostate Cancer.
520 $a This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information.
650 0 $a Urology. $3 645258
650 0 $a Oncology . $3 1253469
650 2 4 $a Oncology. $3 593951
700 1 $a Balaji, K.C. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1108328
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319313399
776 0 8 $i Printed edition: $z 9783319313405
776 0 8 $i Printed edition: $z 9783319524573
856 4 0 $u https://doi.org/10.1007/978-3-319-31341-2
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)